New Antibacterial Agent: Nanobubble Ozone Stored in Liposomes: The Antibacterial Activity of Nanobubble Ozone in Liposomes and Their Thymol Solutions

Alkan, Perihan Erkan; Güneş, Mesut Ertan; Özakın, Cüneyt; Sabancı, A. Ü.

doi:10.1080/01919512.2021.1904205

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Vero cells were treated with NOHAL solution at different concentrations, ranging from 300 ppm to 1600 ppm, for 2, 12 and 24 hours, in the treatment groups in accordance with the previous studies of our group, previous ozone in vitro cytotoxicity assays and recent anti-SARS-CoV-2 effects of ozone therapies. 45–48 Exposure times for treatment were determined by following up the chronic effect, cytotoxicity and the impact on the cell proliferation. The maximum time was calculated in relation to the cells’ doubling time.…”

Section: Methodsmentioning

confidence: 99%

“…A number of studies from different countries including China, Italy, Turkey, Russia and Spain have reported the use of O 3 in many conditions. 4–9 It has been reported that O 3 can reduce inflammation and pain 6 , 8 , 9 , 10 and show bactericidal, 11 fungicidal, 12 virucidal 13 and antiparasitic effects. 14 O 3 is a potent oxidizing agent that is able to react with unsaturated triacylglycerides.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanobubble Ozone Stored in Hyaluronic Acid Decorated Liposomes: Antibacterial, Anti-SARS-CoV-2 Effect and Biocompatibility Tests

Sabancı¹,

Alkan²,

Mujde³

et al. 2022

IJN

Self Cite

View full text Add to dashboard Cite

Purpose SARS-CoV-2-infected individuals may be asymptomatic, and therefore, the virus is highly contagious. We aimed to develop an agent to control viral replication in the upper respiratory tract and to prevent progression of the disease into the lower airways as well as inter-individual transmission. For this purpose, we investigated the antibacterial and antiviral activities of our novel nanobubble ozonated hyaluronic acid-decorated liposomal (NOHAL) solution, developed by using nanotechnology. Methods The MIC levels of NOHAL solution were determined on blood agar cultures of Staphylococcus aureus (ATCC 6538), Streptococcus pneumoniae (ATCC 49619) and Escherichia coli (ATCC 25922). The in vitro anti-viral activity of NOHAL solution was studied using recombinant SARS-CoV-2 copies of the original virus, grown in Vero cells generated by reverse genetic technology. Human primary lung epithelial cells obtained by bronchoscopy or lung resection were used for cell viability tests using flow cytometry analysis. The cytotoxicity testing was performed using the BALB/c 3T3 (CCL-163) cell line. Skin, oral, nasal and ocular irritation tests were performed using New Zealand albino rabbits, Syrian hamsters, BALB c mice and New Zealand albino rabbits of both sexes. Results Bacterial growth was prevented by NOHAL solution in a time-/dose-dependent manner. In vivo or in vitro experiments did not show any toxicity of NOHAL solution. No cytotoxicity was recorded on cell viability. No skin, oral, nasal or ocular toxicities were recorded. In addition, in a SARS-CoV-2 mouse infection model, NOHAL solution diminished the viral RNA levels effectively in nasopharyngeal and lung samples after its prophylactic intranasal application. Conclusion NOHAL solution has the potential to reduce or prevent the spread of SARS-CoV-2 through the nose and/or oral cavity. The clinical efficacy of this solution needs to be tested in order to determine its efficacy in the early phase of COVID-19.

show abstract

Section: Methodsmentioning

confidence: 99%